Does CareFirst BlueCross BlueShield Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab 60 mg/mL, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the protein that drives osteoclast formation and bone resorption. The FDA approved denosumab for postmenopausal women with osteoporosis at high fracture risk in June 2010, and the indication was later broadened to include men with osteoporosis, patients on long-term glucocorticoid therapy, and men receiving androgen-deprivation therapy for non-metastatic prostate cancer. 1

Mechanism and Dosing

Denosumab binds RANKL with high affinity, preventing osteoclast differentiation. Clinicians administer it as a 60 mg subcutaneous injection once every six months, typically in the upper arm, thigh, or abdomen. Because it is a biologic administered in a clinical setting, CareFirst routes it through the medical benefit rather than the pharmacy benefit in most plan configurations.

Clinical Evidence That Drives Coverage Decisions

The FREEDOM trial (N=7,868) demonstrated a 68% relative risk reduction in new vertebral fractures over 36 months compared with placebo (P<0.001). Nonvertebral fractures fell 20% and hip fractures fell 40%. 2 Those numbers come directly from the NEJM 2009 publication by Cummings et al. And are the figures CareFirst's pharmacy and therapeutics committee reviews when setting coverage criteria.

The FREEDOM Extension study followed participants for up to 10 years and showed continued bone mineral density gains with no evidence of a treatment plateau. 3 Fracture risk increased sharply when patients discontinued denosumab without transitioning to another antiresorptive, a clinical fact that shapes CareFirst's continuation criteria.

Guideline Support

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines list denosumab as a first-line option for patients with very high fracture risk and as an alternative when oral bisphosphonates are contraindicated or not tolerated. 4 The Endocrine Society similarly endorses denosumab for postmenopausal osteoporosis in its 2019 clinical practice guideline. 5

How CareFirst BlueCross BlueShield Structures Prolia Coverage

CareFirst operates multiple plan types across Maryland, Washington D.C., and Northern Virginia: commercial PPO and HMO products, Federal Employee Program (FEP) plans, Medicare Advantage plans, and individual marketplace plans. Coverage rules differ across these lines.

Medical Benefit vs. Pharmacy Benefit

Because Prolia is a provider-administered injectable, CareFirst processes most claims under the medical benefit (using J-code J0897) rather than the pharmacy benefit. This distinction matters practically: your medical deductible and out-of-pocket maximum apply, not your prescription drug cost-sharing. For members with a $2,000 medical deductible, the first injection of the calendar year may be entirely out of pocket until that deductible is met.

Prior Authorization Requirements

Prior authorization (PA) is required for denosumab on virtually every CareFirst plan. To obtain PA, the treating clinician typically must document:

• A DEXA scan T-score of -2.5 or below (osteoporosis), or a T-score between -1.0 and -2.5 with a qualifying 10-year FRAX fracture probability
• A diagnosis code from ICD-10 categories M80 (osteoporosis with fracture) or M81 (osteoporosis without fracture), or a relevant secondary cause such as long-term glucocorticoid use (Z79.52)
• Prior trial or documented intolerance of at least one oral bisphosphonate (e.g., alendronate 70 mg weekly for a minimum of 3 to 6 months) in most commercial plan tiers

The National Osteoporosis Foundation recommends initiating pharmacologic therapy when T-score is at or below -2.5 or when a patient has had a hip or vertebral fracture, regardless of BMD. 6 Citing these thresholds explicitly in the PA request strengthens the clinical narrative.

Step Therapy and Bisphosphonate First Requirements

Step therapy is one of the most common reasons for initial PA denial on commercial CareFirst plans. Alendronate (generic, $4, $10/month) is the typical first-step agent because its cost is far below Prolia's wholesale acquisition cost of roughly $1,300 per injection. The AACE 2020 guidelines note that patients with severe osteoporosis (T-score at or below -2.5 plus a prior fracture, or T-score at or below -3.0) may be appropriate candidates for initial high-potency therapy without requiring step therapy. 4 Documenting this severity level precisely can allow the prescribing clinician to request a step-therapy exception at the time of the initial PA submission.

What Documentation Your Doctor Needs to Submit

A well-prepared PA packet reduces the back-and-forth that delays treatment by weeks. The following documentation components consistently appear in CareFirst's coverage criteria and in published PA best-practice guides.

Required Clinical Records

• DEXA scan report showing BMD and T-score at spine and hip, dated within 24 months
• FRAX calculation if T-score is between -1.0 and -2.5 (printout from FRAX tool is acceptable)
• Office notes or pharmacy records showing prior bisphosphonate trial, including duration and reason for discontinuation or contraindication
• Lab results ruling out secondary causes (serum calcium, 25-OH vitamin D, renal function panel), because hypocalcemia is a contraindication listed in the Prolia prescribing information 1
• Letter of medical necessity signed by the treating physician, specifying the fracture-risk context and why alternative agents are unsuitable

Diagnoses That May Bypass Step Therapy

CareFirst, like most commercial insurers, follows clinical criteria that allow exceptions to step therapy when an alternative is medically contraindicated. Bisphosphonate contraindications that commonly support an exception include:

• Creatinine clearance below 35 mL/min (renal impairment; oral bisphosphonates are contraindicated at CrCl <35 mL/min per FDA labeling) 7
• Esophageal disorders such as achalasia or esophageal stricture
• Documented upper GI intolerance with prior bisphosphonate trial
• Inability to remain upright for 30 to 60 minutes after dosing (relevant in neurological or mobility-impaired patients)

The American College of Rheumatology 2022 guideline for glucocorticoid-induced osteoporosis conditionally recommends denosumab as an alternative to bisphosphonates in patients with renal impairment, directly supporting a step-therapy exception request. 8

CareFirst FEP (Federal Employee Program) Coverage Rules

Federal Employee Program members follow Blue Cross Blue Shield Association formulary criteria rather than CareFirst's standard commercial criteria, and the rules differ in meaningful ways.

FEP Basic vs. Standard Options

FEP Standard Option generally places Prolia on a specialty tier with cost-sharing around 20 to 30% of the allowed amount after the deductible. FEP Basic Option may require a higher cost-sharing percentage or a non-preferred tier copayment. Federal employees should request the specific FEP drug list or the current FEP Service Benefit Plan brochure, which the Office of Personnel Management publishes annually. 9

Prior Authorization in FEP

FEP Standard Option requires PA for Prolia with documentation similar to commercial plans: DEXA T-score, fracture history, and prior bisphosphonate exposure. The FEP PA process runs through a separate clinical review unit, so submitting to the standard CareFirst PA line does not satisfy FEP requirements. Clinicians should confirm the correct fax number or portal for FEP submissions before sending documentation.

CareFirst Medicare Advantage Coverage

Medicare Advantage plans administered by CareFirst follow CMS national coverage determinations as a baseline but may add plan-level prior authorization requirements on top of the Medicare Part B framework.

Medicare Part B and the J-Code

Medicare Part B covers provider-administered injectables when the drug is reasonable and necessary, administered in a physician's office or outpatient facility, and supported by a covered diagnosis. Denosumab for osteoporosis qualifies under the "osteoporosis drugs" benefit for certain women if they meet the criteria in the Social Security Act Section 1861(kk). 10 For other covered indications (male osteoporosis, glucocorticoid-induced osteoporosis), coverage runs through Part B as a physician-administered drug.

The FREEDOM trial result of 40% hip fracture reduction 2 anchors the "reasonable and necessary" determination that CMS reviewers apply.

Cost-Sharing Under Medicare Advantage

After the Part B deductible ($240 in 2024), Medicare Advantage plans typically apply a 20% coinsurance for Part B drugs. CareFirst Medicare Advantage plans may cap specialty drug coinsurance or apply fixed copayments depending on the specific plan year's Evidence of Coverage document. Members should request the formulary and Evidence of Coverage for their specific plan year to confirm exact cost-sharing.

What Happens If CareFirst Denies Coverage

Denials fall into two broad categories: non-covered service denials and medical necessity denials. Medical necessity denials are far more common for Prolia and are almost always appealable with additional documentation.

Level 1 Internal Appeal

CareFirst must acknowledge a standard internal appeal within 5 business days and issue a decision within 30 days for non-urgent requests or 72 hours for expedited requests (when delay would seriously jeopardize health). The appeal should include:

• A detailed letter of medical necessity from the prescribing clinician citing AACE 2020 4 and FREEDOM trial data 2
• Peer-reviewed literature supporting the specific clinical scenario
• Evidence of failed or contraindicated step-therapy agents
• Any additional DEXA scan results, fracture documentation, or labs obtained since the initial request

External Review and Independent Organization

If the internal appeal is denied, Maryland, D.C., and Virginia state law (and the ACA for plans subject to it) grants members the right to an independent external review. The external reviewer is a physician with relevant specialty expertise. External review decisions for medical necessity are typically binding on the insurer. The ACA external review process is described in the HHS guidance for non-grandfathered health plans. 11

Expedited Appeal for Urgent Cases

A patient who has already suffered a vertebral fracture and is at imminent risk for a second fracture qualifies for an expedited appeal. Clinician documentation of acute fracture risk and functional decline can support the "urgent" designation that shortens the review timeline from 30 days to 72 hours.

Reducing Out-of-Pocket Costs for Prolia

Even with insurance coverage, cost-sharing for a specialty injectable can reach several hundred dollars per dose. Several legitimate assistance programs exist.

Amgen's Prolia Co-Pay Card

Amgen offers a co-pay assistance program for commercially insured patients that may reduce the patient's cost to $0 per injection, subject to annual limits and eligibility criteria. The program is not available to patients covered by Medicare, Medicaid, or other federal programs. Patients can enroll at Amgen's patient support site or by calling 1-800-772-6436. 12

Patient Assistance Program

For uninsured or underinsured patients who do not qualify for the co-pay card, Amgen's Safety Net Foundation offers free medication. Income thresholds typically require household income at or below 500% of the federal poverty level. The treating clinician's office staff generally manages the application process.

Supplemental Coverage and Medigap

Medicare beneficiaries with a Medigap (Medicare Supplement) policy may have their 20% Part B coinsurance covered by the supplement plan, depending on Medigap plan letter. Medigap Plan G, for example, covers the Part B coinsurance in full after the Part B deductible. 13

Clinical Considerations That Affect the Coverage Conversation

Understanding the clinical evidence behind coverage criteria helps clinicians frame PA requests more precisely and helps patients understand why their insurer is asking for specific documentation.

Fracture Risk Assessment Tools

The FRAX tool, developed at the University of Sheffield and endorsed by the National Osteoporosis Foundation, calculates a 10-year probability of major osteoporotic and hip fracture using clinical risk factors with or without BMD. 14 CareFirst coverage criteria commonly reference FRAX thresholds: a 10-year major fracture probability at or above 20%, or a hip fracture probability at or above 3%, generally supports pharmacologic treatment, including denosumab when other criteria are met.

Vitamin D and Calcium Requirements

The Prolia prescribing label requires all patients to be supplemented with calcium 1,000 mg daily and vitamin D at least 400 IU daily unless hypercalcemia is present. 1 Pre-treatment 25-OH vitamin D levels below 20 ng/mL are associated with higher rates of hypocalcemia following the first denosumab dose, a safety concern that some CareFirst reviewers flag. Documenting vitamin D adequacy (or active supplementation) at the time of PA submission can preempt a clinical hold.

Discontinuation Risks

The FREEDOM Extension data showed that patients who stopped denosumab experienced rapid BMD loss and a rebound increase in vertebral fracture risk within 12 to 24 months of the last dose. 3 This is not merely academic. If a patient loses coverage mid-course, the clinical consequence of an unplanned gap is serious. Clinicians should document a transition plan (typically zoledronic acid 5 mg IV 6 months after the last denosumab dose) in the medical record, and include this in any coverage correspondence that involves potential treatment interruption. The American Society for Bone and Mineral Research 2016 task force report specifically addresses sequential therapy after denosumab discontinuation. 15

Monitoring After Initiation

After the first Prolia injection, clinicians should recheck serum calcium at day 10 to 14, especially in patients with vitamin D insufficiency or renal impairment. Follow-up DEXA scanning is typically recommended at 1 to 2 years to document treatment response. CareFirst continuation PA requests will usually ask for this follow-up BMD data. 16

HealthRX CareFirst Prolia PA Readiness Checklist (Clinical Framework)

The following framework consolidates the documentation elements most likely to result in a first-pass PA approval based on published AACE guidelines 4 and CareFirst's publicly available medical policy criteria. Clinicians can use this as a pre-submission review.

| Documentation Item | Required for Initial PA | Required for Step-Therapy Exception | Required for Continuation PA | |---|---|---|---| | DEXA T-score (spine or hip) | Yes | Yes | Yes (updated within 24 months) | | FRAX 10-year fracture probability | If T-score -1.0 to -2.5 | Optional support | No | | Prior bisphosphonate trial (3 to 6 months) | Yes (commercial plans) | Not required if contraindicated | N/A | | Bisphosphonate contraindication letter | Only if bypassing step therapy | Yes | N/A | | Serum calcium and 25-OH vitamin D | Recommended | Recommended | Yes | | Renal function (CrCl or eGFR) | Recommended | Yes (if CrCl <35 basis) | Yes | | Letter of medical necessity | Yes | Yes | Yes | | Fracture history (imaging report) | If applicable | Strengthens case | N/A | | Transition plan for discontinuation | Optional | Optional | Recommended |

Comparing Prolia to Covered Alternatives Under CareFirst

When step therapy applies and alendronate fails or is contraindicated, clinicians may consider other agents that CareFirst covers before escalating to Prolia. Understanding the comparative coverage field helps avoid repeated PA cycles.

Oral Bisphosphonates

Alendronate (generic) and risedronate (generic) are Tier 1 or Tier 2 on virtually every CareFirst formulary, with $5, $20 monthly copayments. Ibandronate oral monthly is similarly low-cost. These remain the default first step under most commercial PA criteria. The FDA label for alendronate notes that it reduces vertebral fracture risk by approximately 47% over 3 years in postmenopausal osteoporosis. 17

Intravenous Bisphosphonate

Zoledronic acid 5 mg (Reclast) given IV once yearly is an option for patients who cannot tolerate oral bisphosphonates due to GI issues. The HORIZON trial (N=7,736) showed a 70% reduction in morphometric vertebral fractures at 3 years. 18 CareFirst covers zoledronic acid under the medical benefit as well, and its PA criteria are somewhat less stringent than Prolia's because it has a longer post-marketing history and lower WAC.

Raloxifene

Raloxifene 60 mg daily (Evista) is an oral selective estrogen receptor modulator covered on most CareFirst pharmacy tiers at a modest copayment. The MORE trial (N=7,705) showed a 30 to 50% reduction in vertebral fractures but no significant reduction in nonvertebral fractures. 19 It is generally not considered equivalent to denosumab in high-fracture-risk patients.

Teriparatide and Abaloparatide

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents that stimulate bone formation rather than suppressing resorption. CareFirst covers both under the pharmacy benefit (injectable specialty tier) with PA. The AACE 2020 guidelines position anabolic agents as preferred first-line therapy for patients at very high fracture risk, potentially ahead of denosumab in some cases. 4 This means that for very-high-risk patients, a PA for an anabolic agent may actually clear faster than one for Prolia.

Romosozumab

Romosozumab (Evenity) 210 mg monthly subcutaneous injection for 12 months is a sclerostin inhibitor with both anabolic and antiresorptive properties. The ARCH trial (N=4,093) showed a 48% reduction in new vertebral fractures vs. Alendronate at 24 months. 20 CareFirst covers romosozumab with PA, and its criteria typically require similar T-score and fracture documentation as Prolia.